Anti-PD-1/PD-L1 antibodies, such as nivolumab, pembrolizumab, and atezolizumab have shown survival benefit in pretreated patients with NSCLC after failure of platinum doublet chemotherapies, in randomized phase III trials compared to docetaxel monotherapy [6–9]. Here, CD274 is linked to non-small cell lung carcinoma.